Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Latest "Mifepristone Cushing Syndrome" News Stories

05:18 EDT 22nd July 2014 | BioPortfolio

Here are the most relevant search results for "Mifepristone Cushing Syndrome" found in our extensive news archives from over 250 global news sources.

More Information about Mifepristone Cushing Syndrome on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Mifepristone Cushing Syndrome for you to read. Along with our medical data and news we also list Mifepristone Cushing Syndrome Clinical Trials, which are updated daily. BioPortfolio also has a large database of Mifepristone Cushing Syndrome Companies for you to search.

Showing "Mifepristone Cushing Syndrome" News Articles 1–25 of 2,300+

Extremely Relevant

Response in Cushing's Syndrome Treated With Mifepristone

What are strong drivers of response to mifepristone therapy in patients with Cushing disease? Clinical Endocrinology

Cancer: PKA mutations are associated with Cushing syndrome


Neuroendocrine cancer: An activating hotspot mutation in PRKACA provides clues for adrenal Cushing syndrome therapeutics

Cushing’s syndrome: A genetic basis for cortisol excess

An international team of researchers led by an endocrinologist at […]

Cushing's syndrome: Genetic basis for cortisol excess

Cushing’s syndrome has been found to be linked to a genetic basis for cortisol excess. Cortisol is a hormone that is produced by the adrenal gland in response to stressful events, and modulates a whole spectrum of physiological processes. An intern...

Corcept shares halved on mifepristone failure in depression

Corcept Therapeutics saw its stock price cut in half after the company revealed in its first quarter earnings report that mifepristone failed to achieve the primary endpoint in a Phase III clinical trial for the treatment of psychotic depression.

Cushing disease: Often a victim of mistaken identity

The symptoms of Cushing disease are unmistakable to those who suffer from it -- excessive weight gain, acne, distinct colored stretch marks on the abdomen, thighs and armpits, and a lump, or fat deposit, on the back of the neck. Yet the disorder ofte...

Corcept Therapeutics to Announce First Quarter Financial Results and Corporate Update and Host Conference Call

MENLO PARK, CA -- (Marketwired) -- 04/30/14 -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on May 7, 2014. The Company will also host a conference call that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). Conference Call Information To participate, dial 1-888-771-4371 from the United State...

Corcept falls on 1Q14 financial results, trial discontinuation

Corcept Therapeutics Inc. (NASDAQ:CORT) fell $2.03 (50%) to $1.99 on Wednesday after the company reported 1Q14 financial results that missed the Street and disclosed that it discontinued the Phase III Study 14 of mifepristone to treat psychotic depre...

Patients with Cushing’s syndrome experience significant weight loss while taking oral medication

Sinai Hospital of Baltimore endocrinologist, Henry G. Fein, M.D., today presented new research showing that patients with Cushing's syndrome, a rare disease that can lead to extreme weight gain, type 2 diabetes, high blood pressure and psychological...

New Research on Corcept's Korlym(R) for Patients With Cushing's Syndrome to Be Presented at ICE/ENDO 2014

CHICAGO, IL -- (Marketwired) -- 06/19/14 -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders, today announced that new clinical research on Korlym® (mifepristone) will be presented at the joint meeting of the International Socie...

/ CORRECTION - Corcept Therapeutics

CHICAGO, IL -- (Marketwired) -- 06/20/14 -- In the news release, "New Research on Corcept's Korlym® for Patients With Cushing's Syndrome to Be Presented at ICE/ENDO 2014," issued Thursday, June 19, 2014 by Corcept Therapeutics (NASDAQ: CORT), we are advised by the company that the session schedule has now been updated to reflect accurate presentation times with poster numbers added. Complete cor...

Mifepristone: Phase I started

Mifepristone: Phase III discontinued

Genetics: Pinpointing a hotspot in adrenal Cushing syndrome

A gain-of-function point mutation in the gene that encodes one of the catalytic subunits of protein kinase A (PRKACA) in cortisol-producing adrenocortical adenomas has been independently reported by three groups. This hotspot point mutation (c.617T>G...

Serotonin syndrome

What is serotonin syndrome?Serotonin syndrome is a drug induced syndrome characterised by a cluster of dose related adverse effects that are due to increased serotonin concentrations in the central...

Basketball Star's Career Cut Short by Diagnosis of Marfan's Syndrome

Individuals with Marfan's Syndrome (see: Marfan syndrome) are often very tall so I have wondered whether some basketball players have this genetic disorder. A recent article cited a specific instance of this (see: Baylor star Isaiah Austin's NBA pros...

Heartbeat Client Korlym Named Brand of the Year by Pharmaceutical Executive

Pharmaceutical Executive magazine has selected Corcept Therapeutics’ Korlym® as the 2014 Brand of the Year. For the first time, the publication has recognized two brands in two distinct categories – one in the treatment of chronic disease and one in the treatment of orphan status rare disease. Teva Pharmaceutical’s Copaxone® was the Brand of the Ye...

Link between Down syndrome, leukemia uncovered

A connection between people with Down syndrome and having a heightened risk of developing acute lymphoblastic leukemia during childhood has been uncovered by researchers. "For 80 years, it hasn't been clear why children with Down syndrome face a shar...

Improved detection of Down syndrome during pregnancy for younger women

New figures from the National Down Syndrome Cytogenetic Register (NDSCR) based at Queen Mary University of London, reveal the proportion of Down syndrome cases diagnosed antenatally has increased in younger women. Furthermore, Down syndrome diagnoses...

Detection of Down syndrome during pregnancy improves for younger women

(Queen Mary, University of London) New figures from the National Down Syndrome Cytogenetic Register based at Queen Mary University of London, reveal the proportion of Down syndrome cases diagnosed antenatally has increased in younger women. Furthermo...

GIST With Nephrotic Syndrome as a Paraneoplastic Syndrome

This unusual case documents a patient with GIST of the stomach who presented with refractory nephrotic syndrome. Journal of Medical Case Reports

Aqua Pharmaceuticals, LLC Announces Launch of Cordran® Ointment (flurandrenolide ointment, USP) 0.05%

West Chester-based Aqua Pharmaceuticals, an Almirall company, today announces the launch of Cordran® Ointment (flurandrenolide ointment, USP) 0.05%. Cordran® Ointment is a Class 4 topical corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. “Cordran® is a name well-kn...

Sjögren’s syndrome: common treatment may not be effective

Hydroxychloroquine, often prescribed to people with Sjögren’s syndrome, may not improve symptoms after all, suggests a new study published in the Journal of the American Medical Association. Sjögren’s syndrome is characterised by mouth and eye dryness, pain and fatigue. Despite the wide use of hydroxychloroquine in clinical practice, evidence regarding its efficacy is limited. A […]

NREF president receives Harvey Cushing Medal from AANS

Each year, the American Association of Neurological Surgeons (AANS) recognizes a neurosurgeon who has made significant contributions to the neurosurgical specialty through leadership, service and dedication.

Search BioPortfolio:

News Quicklinks